Articles · HRT
Estrogen Delivery Methods and Clot Risk
How the route you take estrogen changes its metabolism, safety, and symptom control.
Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.
When women weigh up HRT, the question is usually whether to take it at all. Less discussed is that how you take estrogen matters clinically, not just for convenience. The route changes how estrogen is processed, its clot risk, and how steady your levels are day to day.
Current UK and US guidelines recommend estrogen through the skin (transdermal) for most women, and especially for those with heart or clotting risk factors.[1][2] Knowing why helps you have a more useful conversation with your doctor.
First-Pass Through the Liver
When you swallow an estrogen tablet, it is absorbed from the gut and goes straight to the liver before it reaches the rest of the body. This is called first-pass liver metabolism, and it has effects.[3]
A surge of estrogen makes the liver produce more of several proteins:
- Clotting factors (factor VII, fibrinogen): raises blood clotting
- Sex hormone-binding globulin (SHBG): binds estrogen and lowers how much is active
- C-reactive protein (CRP): rises with oral estrogen
- Triglycerides: rise with oral estrogen
None of these are necessarily dangerous in a healthy woman with no other risk factors. But they matter if you have risk factors for clots, heart disease, or migraine, and they are extra metabolic work for a result you can get without them.
Transdermal Estrogen Skips the Liver
Patches, gels, and sprays send estrogen through the skin straight into the bloodstream, past the gut and liver. The estrogen that reaches your circulation is essentially the same estradiol your ovaries used to make, handled the same way.[3]
The clinical differences are real:
No rise in clotting factors. Several studies find that transdermal estrogen does not raise the risk of venous thromboembolism (VTE), while oral estrogen raises it 2 to 4 fold.[4][5] The ESTHER study (2007) found no meaningful VTE increase for transdermal users compared with non-users, while oral users had an odds ratio of 4.2.[4]
No rise in stroke risk. A large UK study using the Clinical Practice Research Datalink found no increase in stroke risk with transdermal estrogen. Oral estrogen raised the risk of ischaemic stroke, and more so at higher doses.[6]
Steadier levels. Oral estrogen creates a peak and then a trough with each dose. Transdermal delivery, patches especially, holds estradiol at a more even level through the day.[3]
The Three Transdermal Forms
Patches are the most studied. Twice-weekly patches (changed on days 1 and 4 of the week) and weekly patches are both available. They give the steadiest levels and the least daily effort. A minority of users get skin reactions at the sticky patch site; rotating where you put it helps.
Gels go on daily to the arm, thigh, or abdomen. They absorb in a few minutes and are invisible once dry. Gel lets you adjust the dose in small steps, which some women find useful in perimenopause when needs shift. The main thing to watch is avoiding skin contact with partners or children before it has fully dried.
Sprays work like gels. One pump delivers a measured dose to the forearm. Daily use, brief drying time.
The Progestogen Part
Women who still have a womb need a progestogen alongside estrogen to protect the lining from overgrowth. The type matters.
Micronised progesterone (Utrogestan in the UK, Prometrium in the US) is identical to the progesterone your body makes. It is better tolerated than synthetic progestogens for most women, with neutral or helpful effects on mood, sleep, and possibly breast cancer risk.[7][8] It is taken orally at night, using its mild sedative effect, or vaginally.
Synthetic progestogens (medroxyprogesterone acetate, norethisterone, levonorgestrel, dydrogesterone) are not the same molecule as natural progesterone and act on receptors differently. MPA, used in the original WHI trial, has been linked to a higher breast cancer risk in combined HRT than micronised progesterone.[7]
The Mirena IUS releases levonorgestrel locally in the womb with very little reaching the rest of the body. For women who want womb protection with low progestogen exposure elsewhere, it is worth discussing with a gynaecologist.
Practical Comparison
| Method | Frequency | Liver effect | VTE risk | Level stability | Notes |
|---|---|---|---|---|---|
| Oral tablet | Daily | Yes | Increased | Peak and trough | Cheapest; avoid with clot risk |
| Twice-weekly patch | Every 3 to 4 days | No | Not increased | Good | Most studied; some skin reactions |
| Weekly patch | Weekly | No | Not increased | Very good | Convenient; fewer changes |
| Gel | Daily | No | Not increased | Good | Flexible dosing; needs drying time |
| Spray | Daily | No | Not increased | Good | Similar to gel; metered dose |
Choosing a Form
The choice should account for:
- Personal or family history of blood clots: transdermal is strongly preferred
- Heart risk factors: transdermal is preferred
- Skin sensitivity: if patches cause reactions, gel or spray may suit better
- What you will actually stick to: some women find a daily gel easier to remember; others prefer the twice-weekly patch
- Dose flexibility: gel is easier to adjust for the shifting needs of early perimenopause
- Progestogen preference: if you have a womb and want low progestogen exposure elsewhere, a Mirena IUS with transdermal estrogen is worth considering
The aim is the form that best balances how well it works, safety for your risk profile, and the odds you will use it consistently.
References
[1] NICE Guideline NG23. (2023). Menopause: Diagnosis and Management. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23
[2] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028
[3] Stanczyk, F. Z., Bhavnani, B. R. (2014). Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe? Journal of Steroid Biochemistry and Molecular Biology, 142, 30-38. https://doi.org/10.1016/j.jsbmb.2013.11.011
[4] Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens. The ESTHER Study. Circulation, 115(7), 840-845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
[5] Sweetland, S., Beral, V., Balkwill, A., et al. (2012). Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. Journal of Thrombosis and Haemostasis, 10(11), 2277-2286. https://doi.org/10.1111/j.1538-7836.2012.04919.x
[6] Renoux, C., Dell’Aniello, S., Garbe, E., Suissa, S. (2010). Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ, 340, c2519. https://doi.org/10.1136/bmj.c2519
[7] Fournier, A., Berrino, F., Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103-111. https://doi.org/10.1007/s10549-007-9523-x
[8] Schüssler, P., Kluge, M., Yassouridis, A., et al. (2008). Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology, 33(8), 1124-1131. https://doi.org/10.1016/j.psyneuen.2008.05.013
Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.